A Multicenter Real‐World Study of Outcomes in Patients With Relapsed/Refractory Diffuse Large B‐Cell Lymphoma Treated With a Polatuzumab Vedotin‐Based Regimen in a Compassionate Use Program in Malaysia
- 27 June 2025
- journal article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 22 (1) , 41-49
Abstract
Background: Polatuzumab vedotin + bendamustine + rituximab (Pola‐BR) was recently approved in Malaysia for treating relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). A multicenter retrospective study was conducted to assess the effectiveness of this regimen among patients in a compassionate use program. Objective: To determine treatment response and survival rates for R/R DLBCL patients treated with Pola‐BR in Malaysia. Methodology: Safety and efficacy data of 23 adults with R/R DLBCL treated with Pola‐BR at nine centers in Malaysia (September 2019–February 2021) were used. Of the 23 patients, 13 received six cycles of Pola‐BR. The median follow‐up was 10 months (1–37 months). The primary endpoint was complete response (CR) rate; secondary endpoints were overall survival (OS), progression‐free survival (PFS), and adverse events (AEs). Results: The overall response rate was 56.5%, with 34.8% achieving CR. The 1‐, 2‐, and 3‐year OS rates were 51.6%, 51.6%, and 44.2%, respectively, with a median OS of 27 months. The 1‐ and 2‐year PFS rates were 48.2% and 41.3%, respectively, with a median PFS of 10 months; 60% of the nonresponders had progressive disease. Cox proportional hazard regression analysis showed that bulky disease was a significant hazard for disease progression. A total of 42 AEs were recorded, of which 66.7% were grade ≥ 3 AEs; 90.5% of the AEs were hematological and resolved with treatment; only one patient succumbed to neutropenic sepsis. Conclusions: Pola‐BR has a favorable safety profile for R/R DLBCL treatment in Malaysia, although larger sample sizes and longer follow‐ups are needed to confirm these results.Keywords
This publication has 32 references indexed in Scilit:
- Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2022
- Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based TherapyHemaSphere, 2022
- FDA Approval Summary: Selinexor for Relapsed or Refractory Diffuse Large B-Cell LymphomaThe Oncologist, 2021
- 2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and managementAmerican Journal of Hematology, 2021
- Diffuse Large B-Cell LymphomaNew England Journal of Medicine, 2021
- Real‐life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B‐cell lymphomasHematological Oncology, 2021
- Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experienceLeukemia & Lymphoma, 2020
- Significance of bulky mass and residual tumor—Treated with or without consolidative radiotherapy—To the risk of relapse in DLBCL patientsCancer Medicine, 2020
- EPIDEMIOLOGY REVIEW OF LYMPHOMA IN A SINGLE INSTITUTION IN MALAYSIAHematological Oncology, 2019
- Outcomes of primary refractory diffuse large B‐cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab eraBritish Journal of Haematology, 2016